CYP2C19 and cancer: We first compared the total EET concentrations in CYP2C19 knockdown cells, or cells treated with 500 nM 17-ODYA (a CYP450 enzyme inhibitor known to lower EET levels in several cancer cell lines) [28], 500 nM HET0016 (a non-specific CYP inhibitor), and 500 nM AUDA (a specific sEH inhibitor) (Fig. 4b).